These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 27752537)

  • 1. Modeling practice effects in healthy middle-aged participants of the Alzheimer and Families parent cohort.
    Sánchez-Benavides G; Gispert JD; Fauria K; Molinuevo JL; Gramunt N
    Alzheimers Dement (Amst); 2016; 4():149-158. PubMed ID: 27752537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aging, Practice Effects, and Genetic Risk in the Wisconsin Registry for Alzheimer's Prevention.
    Jonaitis EM; Koscik RL; La Rue A; Johnson SC; Hermann BP; Sager MA
    Clin Neuropsychol; 2015; 29(4):426-41. PubMed ID: 26012360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective Evaluation of Cognitive Health and Related Factors in Elderly at Risk for Developing Alzheimer's Dementia: A Longitudinal Cohort Study.
    Udeh-Momoh C; Price G; Ropacki MT; Ketter N; Andrews T; Arrighi HM; Brashear HR; Robb C; Bassil DT; Cohn M; Curry LK; Su B; Perera D; Giannakopoulou P; Car J; Ward HA; Perneczky R; Novak G; Middleton L
    J Prev Alzheimers Dis; 2019; 6(4):256-266. PubMed ID: 31686098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein epsilon4 and neuropsychological performance in Alzheimer's disease and vascular dementia.
    McGuinness B; Carson R; Barrett SL; Craig D; Passmore AP
    Neurosci Lett; 2010 Oct; 483(1):62-6. PubMed ID: 20678545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APOE-ε4 risk variant for Alzheimer's disease modifies the association between cognitive performance and cerebral morphology in healthy middle-aged individuals.
    Cacciaglia R; Molinuevo JL; Falcón C; Sánchez-Benavides G; Gramunt N; Brugulat-Serrat A; Esteller M; Morán S; Fauria K; Gispert JD;
    Neuroimage Clin; 2019; 23():101818. PubMed ID: 30991302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of APOE status on cognitive maintenance in healthy elderly persons.
    Zehnder AE; Bläsi S; Berres M; Monsch AU; Stähelin HB; Spiegel R
    Int J Geriatr Psychiatry; 2009 Feb; 24(2):132-41. PubMed ID: 18615849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Independent effects of white matter hyperintensities on cognitive, neuropsychiatric, and functional decline: a longitudinal investigation using the National Alzheimer's Coordinating Center Uniform Data Set.
    Puzo C; Labriola C; Sugarman MA; Tripodis Y; Martin B; Palmisano JN; Steinberg EG; Stein TD; Kowall NW; McKee AC; Mez J; Killiany RJ; Stern RA; Alosco ML
    Alzheimers Res Ther; 2019 Jul; 11(1):64. PubMed ID: 31351489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years.
    Wattmo C; Wallin ÅK
    Alzheimers Res Ther; 2017 Aug; 9(1):70. PubMed ID: 28859660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment.
    Caselli RJ; Reiman EM; Locke DE; Hutton ML; Hentz JG; Hoffman-Snyder C; Woodruff BK; Alexander GE; Osborne D
    Arch Neurol; 2007 Sep; 64(9):1306-11. PubMed ID: 17846270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropsychological signs of Alzheimer's disease 8 years prior to diagnosis.
    Schmid NS; Taylor KI; Foldi NS; Berres M; Monsch AU
    J Alzheimers Dis; 2013; 34(2):537-46. PubMed ID: 23254631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APOE genotype, memory test performance, and the risk of Alzheimer's disease in the Canadian Study of Health and Aging.
    Klages JD; Fisk JD; Rockwood K
    Dement Geriatr Cogn Disord; 2003; 15(1):1-5. PubMed ID: 12457072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
    Susanto TA; Pua EP; Zhou J;
    J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of reliable evidence for a distinctive ε4-related cognitive phenotype that is independent from clinical diagnostic status: findings from the Australian Imaging, Biomarkers and Lifestyle Study.
    Foster JK; Albrecht MA; Savage G; Lautenschlager NT; Ellis KA; Maruff P; Szoeke C; Taddei K; Martins R; Masters CL; Ames D;
    Brain; 2013 Jul; 136(Pt 7):2201-16. PubMed ID: 23737466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. White matter microstructure is altered in cognitively normal middle-aged APOE-ε4 homozygotes.
    Operto G; Cacciaglia R; Grau-Rivera O; Falcon C; Brugulat-Serrat A; Ródenas P; Ramos R; Morán S; Esteller M; Bargalló N; Molinuevo JL; Gispert JD;
    Alzheimers Res Ther; 2018 May; 10(1):48. PubMed ID: 29793545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential Aging Trajectories of Modulation of Activation to Cognitive Challenge in APOE ε4 Groups: Reduced Modulation Predicts Poorer Cognitive Performance.
    Foster CM; Kennedy KM; Rodrigue KM
    J Neurosci; 2017 Jul; 37(29):6894-6901. PubMed ID: 28652414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cortical β-amyloid burden, gray matter, and memory in adults at varying APOE ε4 risk for Alzheimer's disease.
    Mecca AP; Barcelos NM; Wang S; Brück A; Nabulsi N; Planeta-Wilson B; Nadelmann J; Benincasa AL; Ropchan J; Huang Y; Gelernter J; Van Ness PH; Carson RE; van Dyck CH
    Neurobiol Aging; 2018 Jan; 61():207-214. PubMed ID: 29111487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease.
    Bizzarro A; Marra C; Acciarri A; Valenza A; Tiziano FD; Brahe C; Masullo C
    Dement Geriatr Cogn Disord; 2005; 20(4):254-61. PubMed ID: 16103669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Memory performance in healthy elderly without Alzheimer's disease: effects of time and apolipoprotein-E.
    Mayeux R; Small SA; Tang M; Tycko B; Stern Y
    Neurobiol Aging; 2001; 22(4):683-9. PubMed ID: 11445269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidental findings on brain MRI of cognitively normal first-degree descendants of patients with Alzheimer's disease: a cross-sectional analysis from the ALFA (Alzheimer and Families) project.
    Brugulat-Serrat A; Rojas S; Bargalló N; Conesa G; Minguillón C; Fauria K; Gramunt N; Molinuevo JL; Gispert JD
    BMJ Open; 2017 Mar; 7(3):e013215. PubMed ID: 28341686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.